Literature DB >> 26081192

USP39 promotes the growth of human hepatocellular carcinoma in vitro and in vivo.

Xianwen Yuan1, Xitai Sun1, Xiaolei Shi1, Chunping Jiang1, Decai Yu1, Weiwei Zhang1, Wenxian Guan2, Jianxin Zhou1, Yafu Wu1, Yudong Qiu1, Yitao Ding1.   

Abstract

Ubiquitin specific protease 39 (USP39) plays an important role in mRNA splicing. In the present study, we investigated the role of USP39 in regulating the growth of hepatocellular carcinoma (HCC). We detected USP39 expression in more than 100 HCC clinical samples. The USP39 expression was significantly higher in the tumor tissues compared to the adjacent normal tissues, and was strongly associated with the pathological grade of HCC. USP39 knockdown inhibited cell proliferation and colony formation in vitro in the HepG2 cells, while upregulation of USP39 promoted tumor cell growth. FCM assay showed that USP39 knockdown led to G2/M arrest and induced apoptosis in the HepG2 cells. USP39 knockdown by shRNA inhibited xenograft tumor growth in nude mice. Moreover, USP39 knockdown led to the upregulation of p-Cdc2 and downregulation of p-Cdc25c and p-myt1, while the expression of total Cdc2, Cdc25c and myt1 was not changed in the USP39-knockdown cells. We also found that p-Cdc2 was decreased in the USP39-overexpressing cells and was upregulated in the xenografted tumors derived from the HepG2/KD cells from nude mice. Meanwhile, the expression levels of FoxM1 and its target genes PLK1 and cyclin B1 were decreased in the USP39-knockdown cells. These results suggest that USP39 may contribute to FoxM1 splicing in HCC tumor cells. Our data indicate that USP39 knockdown inhibited the growth of HCC both in vitro and in vivo through G2/M arrest, which was partly achieved via the inhibition of FoxM1 splicing.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26081192     DOI: 10.3892/or.2015.4065

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  14 in total

1.  MiR-1281, a p53-responsive microRNA, impairs the survival of human osteosarcoma cells upon ER stress via targeting USP39.

Authors:  Jian Jiang; Binbin Ma; Xiaojie Li; Wenlong Jin; Chuanchun Han; Ling Wang; Hong Wang
Journal:  Am J Cancer Res       Date:  2018-09-01       Impact factor: 6.166

2.  USP39 regulates the growth of SMMC-7721 cells via FoxM1.

Authors:  Xianwen Yuan; Xitai Sun; Xiaolei Shi; Chunping Jiang; Decai Yu; Weiwei Zhang; Yitao Ding
Journal:  Exp Ther Med       Date:  2017-02-10       Impact factor: 2.447

Review 3.  Research Progress of DUB Enzyme in Hepatocellular Carcinoma.

Authors:  Jie Zhao; Jinhui Guo; Yanan Wang; Qiancheng Ma; Yu Shi; Feng Cheng; Qiliang Lu; Wen Fu; Guangxiong Ouyang; Ji Zhang; Qiuran Xu; Xiaoge Hu
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

4.  USP39 facilitates breast cancer cell proliferation through stabilization of FOXM1.

Authors:  Zhenwang Zhang; Wu Liu; Xiajun Bao; Tian Sun; Jiawei Wang; Mengxi Li; Chao Liu
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

5.  Ubiquitin-specific protease 39 is overexpressed in human lung cancer and promotes tumor cell proliferation in vitro.

Authors:  Zhifeng Lin; Liwen Xiong; Qiang Lin
Journal:  Mol Cell Biochem       Date:  2016-09-15       Impact factor: 3.396

6.  Knockdown of USP39 induces cell cycle arrest and apoptosis in melanoma.

Authors:  Yuan Zhao; Bo Zhang; Yu Lei; Jingying Sun; Yaohua Zhang; Sen Yang; Xuejun Zhang
Journal:  Tumour Biol       Date:  2016-07-25

7.  Overexpression of USP39 predicts poor prognosis and promotes tumorigenesis of prostate cancer via promoting EGFR mRNA maturation and transcription elongation.

Authors:  Yi Huang; Xiu-Wu Pan; Lin Li; Lu Chen; Xi Liu; Jian-Lei Lu; Xiao-Mei Zhu; Hai Huang; Qi-Wei Yang; Jian-Qing Ye; Si-Shun Gan; Lin-Hui Wang; Yi Hong; Dan-Feng Xu; Xin-Gang Cui
Journal:  Oncotarget       Date:  2016-04-19

8.  RNA splicing factor USP39 promotes glioma progression by inducing TAZ mRNA maturation.

Authors:  Kaikai Ding; Jianxiong Ji; Xin Zhang; Bin Huang; Anjing Chen; Di Zhang; Xingang Li; Xinyu Wang; Jian Wang
Journal:  Oncogene       Date:  2019-07-22       Impact factor: 9.867

9.  Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.

Authors:  Lei Xu; Bin Zhang; Wenlan Li
Journal:  Mol Med Rep       Date:  2021-02-12       Impact factor: 2.952

Review 10.  Identifying Novel Actionable Targets in Colon Cancer.

Authors:  Maria Grazia Cerrito; Emanuela Grassilli
Journal:  Biomedicines       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.